A potent hexapeptide GHRP studied for GH release via ghrelin-receptor pathways, with additional endocrine readouts.
Pre-loaded with a typical Hexarelin vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for Hexarelin. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 35 mcg – 150 mcg | single bolus exposures in study sessions | intravenous | Imbimbo et al. rising-dose IV study in healthy men Published IV doses were 0.5, 1, and 2 mcg/kg. Absolute mcg above assumes roughly 70 kg body mass for schema display. |
| 100 mcg – 200 mcg | once or twice daily in secondary protocol summaries | subcutaneous | Commonly cited subcutaneous research-protocol ranges Secondary research summaries often discuss 100-200 mcg SC amounts; these are not standardized medical regimens. |
People searching this page also look for: hexarelin peptide dosage.
Hexarelin is a synthetic six-amino-acid growth hormone-releasing peptide (GHRP) and ghrelin-mimetic secretagogue. In human and animal studies from the 1990s onward, it produced robust, dose-dependent GH release after intravenous or other parenteral administration, often with smaller concurrent rises in prolactin, ACTH, and cortisol.
Researchers use hexarelin as a benchmark GHS-R agonist when mapping pituitary responsiveness, aging-related GH decline, feedback inhibition by exogenous GH, and comparative potency versus GHRP-2, GHRP-6, or later secretagogues. Some preclinical literature also explores cardiovascular and non-endocrine actions, though the densest evidence base remains endocrine pharmacology.
Research-grade hexarelin is Research Use Only. It is not FDA-approved for human therapy and is not for human consumption. Reported mcg/kg and absolute mcg figures below are literature references only.
Hexarelin activates the growth hormone secretagogue receptor (GHS-R1a), the same receptor engaged by ghrelin. Pituitary and hypothalamic actions promote GH secretion and can synergize with GHRH-pathway input. Unlike pure GHRH analogs, GHRPs commonly influence additional axes at higher exposures, which is why prolactin and HPA-axis readouts appear in classic human dose-response papers.
GH secretagogue pharmacology · pituitary stimulation testing models · aging and GH-axis responsiveness · GHRH and GHRP combination physiology · comparative GHS-R agonist research
Neuroendocrinology labs and GH-axis pharmacology groups are the core users. Historical clinical-research units also used hexarelin in controlled dose-response and repeated-administration studies in healthy volunteers and selected patient cohorts.
Store lyophilized hexarelin cold and dry. After reconstitution, refrigerate, protect from light, and avoid unnecessary freeze-thaw cycles.
Hexarelin is classically studied with GHRH or long-acting GHRH analogs such as CJC-1295 because dual-receptor input can amplify GH output. Comparative designs versus ipamorelin or GHRP-2 are also common when the experimental goal is selectivity and side-axis activation profiling.
The questions people actually search for, answered plainly.
Human IV dose-response work used about 0.5-2 mcg/kg. Secondary subcutaneous protocol charts often cite roughly 100-200 mcg per exposure. These are reference values, not advice.
Classic literature describes hexarelin as a highly potent GH secretagogue, often comparable to or stronger than earlier GHRP-6 benchmarks depending on model and route.
No. Studies also report modest increases in prolactin, ACTH, and cortisol at effective GH-releasing exposures, which is part of its pharmacologic fingerprint.
No. It is RUO laboratory material, not an FDA-approved therapy, and not for human consumption.
Because repeated administration can attenuate the GH response over time. Desensitization and feedback are important experimental variables.
Yes. Many research discussions pair a GHRP/GHS-R agonist with a GHRH analog to examine complementary GH-axis inputs.
Research suppliers commonly offer 2 mg or 5 mg lyophilized vials for reconstitution into working solutions.
Primary literature on Hexarelin. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides